EW Edwards Lifesciences Corp

  1. Stocks
  2. Healthcare
  3. NYSE: EW

Price (delayed)

$105.5

Market cap

$60.66B

P/E Ratio

59.6

Dividend/share

N/A

EPS

$1.77

Enterprise value

$58.26B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 70

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, ...

Highlights
EW's quick ratio is up by 19% year-on-year and by 2.6% since the previous quarter
EW's gross profit is up by 13% year-on-year and by 2.7% since the previous quarter
The price to earnings (P/E) is 73% higher than the 5-year quarterly average of 34.5 and 26% higher than the last 4 quarters average of 47.4
The net income has contracted by 25% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.edwards.com
Peers: BSX MMSI LMAT ICUI

Key stats

What are the main financial stats of EW

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
-0.29%
1 week
4.64%
1 month
22.12%
1 year
23.28%
YTD
23.75%
QTD
22.22%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$6.67B
Gross profit
$5.21B
Operating income
$1.18B
Net income
$1.02B
Gross margin
78%
Net margin
15.3%
The net margin has contracted by 34% YoY
The net income has contracted by 25% YoY
The company's operating margin fell by 24% YoY and by 2.2% QoQ
The operating income has contracted by 14% YoY

Price vs fundamentals

How does EW's price correlate with its fundamentals

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
EW P/E details
P/E
59.6
P/B
5.6
P/S
9.11
EV/EBIT
39.19
EV/EBITDA
34.59
EV/Sales
8.73
The price to earnings (P/E) is 73% higher than the 5-year quarterly average of 34.5 and 26% higher than the last 4 quarters average of 47.4
The company's EPS fell by 25% YoY
The stock's price to book (P/B) is 20% less than its 5-year quarterly average of 7.0 but 20% more than its last 4 quarters average of 4.7
The equity has grown by 6% year-on-year and by 2.3% since the previous quarter
The P/S is 17% above the last 4 quarters average of 7.8 but 6% below the 5-year quarterly average of 9.7
EW's revenue is up by 13% year-on-year and by 2.5% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
EW's return on assets is down by 29% year-on-year
Edwards Lifesciences's return on equity has decreased by 28% YoY
The company's return on sales fell by 19% YoY
The company's return on invested capital fell by 15% YoY

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
EW's quick ratio is up by 19% year-on-year and by 2.6% since the previous quarter
The company's current ratio rose by 15% YoY
The debt is 94% less than the equity
The company's debt to equity fell by 14% QoQ and by 14% YoY
The equity has grown by 6% year-on-year and by 2.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.